Curia to expand manufacturing capacity

By The Science Advisory Board staff writers

August 19, 2021 -- Curia plans to expand its commercial manufacturing capacity at its facility in Rensselaer, NY, and is investing more than $35 million in the expanded manufacturing and product-handling capabilities for complex small molecules.

Curia, formerly known as Albany Molecular Research, said the expansion will include new vessel capacities that more than double the site's batch-size scaling and product output. It will allow for the introduction of a variety of new products and enable Curia to meet growing demand for high-potency active pharmaceutical ingredient (API) manufacturing.

Curia's Rensselaer, NY, facility. Image courtesy of Curia.

The expansion will generate new jobs in Rensselaer and is expected to be completed within 18 months, the company said.

Curia to acquire LakePharma
Curia, formerly known as Albany Molecular Research, has inked a deal to acquire private biologics firm LakePharma.
Curia to acquire Integrity Bio
Curia, formerly known as Albany Molecular Research, has inked a definitive agreement to acquire drug formulation and fill-finish provider Integrity Bio.
AMRI rebrands as Curia
Albany Molecular Research (AMRI) has changed its name to Curia, effective July 12.
AMRI strategically expands to produce rare disease products
Albany Molecular Research (AMRI) has expanded access to its accelerated solutions platform from research and development to manufacturing for orphan and...
AMRI ups hydroxychloroquine sulfate API production
AMRI Global will boost production of hydroxychloroquine sulfate active pharmaceutical ingredients (API) due to its potential effectiveness in treating...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter